Emergency! The National Health Service has released a catalogue of recent developments.

Medicine Network October 19 - On Saturday, October 17, the Health Insurance Bureau is not closed.
health insurance bureau official website issued "on the 2020 National Health Insurance Drug Catalog adjustment form review results of the inquiry notice." The contents of the
announcement reveal two aspects of information: First, the "2020 National Health Insurance Drug Catalog Adjustment Through Formal Review of the List of Declared Medicines (Public Draft)" released to the public on September 18th, is not the final formal review, that is, the list of experts who will be eligible for the next round of health care catalog adjustments and negotiations.
, the current process of adjusting the health-care directory lags slightly behind previous programs.
Because according to the 2020 National Health Insurance Drug Catalog Adjustment Work Programme previously published by the Health Insurance Administration, this year's health care catalog adjustment is divided into five stages: preparation, declaration, expert review, negotiation and bidding, and publication of the results.
, the negotiation and bidding phase is completed between October and November, with the results announced at 12 November.
has been in progress for more than half in October and is currently under way in the reporting phase (August-September 2020), which, as described in the programme, includes the publication of reporting guidelines.
the scope of the 2020 drug catalog adjustment, the recipient of eligible declaration subjects to submit the necessary information to the National Health Insurance Administration Medical Insurance Center in accordance with the provisions.
to conduct a formal review of the information and to make public medicines that have passed the formal review.
so, according to the number of review lists published in its current form, if expert reviews, negotiations and bids are completed in October, either the negotiation cycle will be extended or more health care experts will be involved.
150 varieties of drug prices will be negotiated in 2019 for a period of three days.
This year's medical insurance catalog of more than 700 drugs, many controversial varieties, popular varieties, provincial supplements will enter a battle for votes and negotiations, and some foreign pharmaceutical companies are to this year to put their global heavyweight varieties on China's negotiating table, the significance of which is self-evident.
E drug managers deliberately combed through some of the points and questions about this year's health-care catalog adjustment, and looked forward to readers participating in the discussion at the end of the article and asking more questions about your concerns.
will the 1.PD-1/L1 pattern change? This is perhaps the most-watched issue of the year and a major collision between multinational, innovative and local traditional pharmaceutical companies.
2020 PD-1/L1 first echelon of eight products officially gathered, in groups, in addition to last year has entered the health insurance Zinda, three innovative pharmaceutical companies or traditional leaders from the local will face off with four multinational giants.
last year Xinda slashed prices and had exclusive access to Medicare, adapting to the classic Hodgkin's lymphoma.
And this year the industry generally believed that must fall below the price of Xinda to be able to negotiate successfully, while this year PD-1 approved the adaptation certificate is more extensive, K drug maximum, up to 5, Hengrui strong, and later has been rapidly expanded to 4 adaptation certificates, and this year each in the "big adaptation certificate" have been achieved, health insurance how to consider its fund pressure, after all, lung cancer this adaptation certificate is much larger than last year's lymphoma, and for pharmaceutical companies next market is also greater.
fact that you want to get health care.
But whether MNC can cut prices with the determination of the strongman to break his wrists, and get headquarters recognition, balance the various national markets, the challenge is enormous, while local companies are worried about whether they will kill a half way to bite the gold, to pull the price down to a whole new level, especially Hang Seng.
Henrui itself is highly commercialized and adapts to the rapid expansion of the certificate, once a sharp price cut into health insurance, perhaps for several others almost count as a "disaster."
addition, according to the relevant forecasts, China's PD-1 market will reach more than 60 billion yuan, if the price war started again, this market can be so large as previously expected? Can Hengrui, Merca East and Xinda continue to lead the market? 2. Will the success rate brush a new low? The 2020 health-care directory adjustment was opened in the form of corporate filings, and there are currently about 750 drugs on the list of first-instance cases (actually less than that figure, some of which meet multiple access conditions and are therefore double-counted).
Among them, this year due to the provincial health insurance directory out, in line with the entry of five or more provincial health insurance directory can be applied for inclusion in the national health insurance, so this year an influx of drugs in line with this situation, accounting for more than 65% of the first-instance drugs.
large quantities of drugs through the first instance, followed by expert review and negotiation (bidding) procedures, the pass rate is still unknown.
97 of the 150 drugs negotiated for health care in 2019.
this year's varieties are more complex, the industry is widely expected to hit a new low pass rate, and there is bold speculation that it can pass 100 even higher levels.
the door to national health insurance open after the cancellation of the provincial supplement? Local supplements were once the most important access route in addition to the adjustment of the national health insurance catalogue.
statistics from 15 provinces and districts in 2017 and 2018 show that at least 200 additional drugs have been added to the category B catalogue of health insurance in each province, with 500 additional drugs in some provinces and districts, and nearly 2,000 additional drugs in Shanghai.
local health insurance has lost the power to increase and reduce the total number of Medicare Class B drugs by 15%, and once drugs miss the opportunity for national health insurance adjustment, it is difficult to seek access breakthroughs from the provincial and district levels.
door to local supplements has been closed, and drug access has focused on the adjustment of the national health-care directory.
the chances of the 493 provincial-level supplements passed this year to enter the national health insurance system? How many products can seize the opportunity of national health care must also be a headache for these companies.
4. Who's discounting big when domestic and foreign competitions are duel? This year, local companies will face foreign investors in a series of direct competition.
such as third-generation EGFR targeted drugs.
Astrain's Ositinib has entered the national health insurance system, but this year needs to redefine the payment criteria, and this year approved the first line of medication, so it will face a renewal negotiation, and proud of the country's first three-generation EGFR targeted drug Amedini just approved this year, two heavyweight products will face a head-to-head showdown.
a similar scenario is BTK inhibitors, which will be negotiated this year in Zebtini, the state of Bezis, while Ibdini faces changes to health-care payment standards.
addition, several diabetes drugs, AIDS drugs, etc. have direct competition between domestic and foreign investment.
For foreign-funded enterprises, there are many difficulties in reducing prices, the need to balance the global market, and headquarters support, so that domestic and foreign enterprises who can play a greater discount, look full.
5. Can you get in when the family is focused on fighting for health insurance? In this year's health care negotiations, a large number of MNC's heavyweight products will be negotiated.
, for example, is Lilly's number one product, generating more than $4 billion in global sales in 2019, accounting for about 20 percent of its full-year revenue, and is one of the most important products it has launched in China in recent years.
whether this fist product can enter health care in China is also important for Lilly.
The most important GLP-1 subjectors on the global market at present are noro and Nord's liraglutide, somalutide, liraglutide has taken the lead in the domestic market, into the health insurance directory, and benalutide from Shanghai Renhua Bio will also be negotiated this year.
Lilly is under a lot of pressure.
Addition, Sanofi's $2 billion heavyweights, Dabie, Gilead's Bittovi and Ji Iv, Novart's Sukin Single Resistance, and so on, all have to fight for health care negotiations this year.
health insurance funds be fully acceptable to these big varieties? The pressure on health care is not small.
6. How is the negotiation method determined? With so many product adjustments and fierce competition in this year's health-care catalog, the national health-care agency's approach and strategy is of particular concern.
The bidding negotiations on hepatitis C products last year were an innovative way to bring down the prices of hepatitis C healing products by a very large number, and will more products adopt this year? This year again, there are several from Guangshengtang, Gilead's hepatitis C healing products to declare health insurance, the fate of these products will be what? And the broad-spectrum cancer drug PD-1 and how to negotiate, are the industry's concerns.
7. Will health care continue to break through the tradition? Last year, an AIDS drug from Gilead, JetBlue, negotiated the inclusion of health insurance, changing the way AIDS drugs are accessed in China.
Previously, the state had been managing the drugs in the form of a national free drug catalog, and the success of the negotiations showed the inclusiveness of the health-care catalogue, revolutionizing the single and narrow form of market access for AIDS drugs.
year, at least four AIDS drug applications from Gilead, Xi'an Yangsen, Frontier Biology and other companies were included in the health insurance program.
the 2020 outbreak, whether health insurance will pay for the new vaccine has become the focus of public attention, and the health insurance bureau has actually responded that it is difficult for health funds to bear such a burden.
in fact, in this year's new "Interim Measures for the Administration of Basic Medical Insurance Drug Use", the official has also made it clear that the health insurance directory will not include preventive vaccines.
8. Should local innovation receive some kind of support? In recent years, there have been different ideas about prices in health-care negotiations.
last year's song ceremony surprised many people.
Some industry insiders call on health insurance to support local innovation, for lower drug prices, improve the access of Chinese patients to local innovative products, should be supported, while some foreign-funded enterprises believe that, as the first "original research enterprises", do not agree that domestic and foreign products should be treated differently.
health care would consider such an appeal? 9. Will "971" get health insurance? "971" was controversial, and Green Valley kept a low profile.
rumors that the product was snapped up after the market, many chains said the initial market in short supply.
currently, this product is mainly in the off-hospital market.
if health insurance were to enter the hospital, it would undoubtedly tear the Alzheimer's market apart again.
"971" was approved for listing last year, but its existing clinical data have been questioned.
Although the follow-up also needs to supplement clinical data, but the National Drug Administration approved the listing of products, it is equivalent to a certain degree of endorsement, but to enter the health insurance also need to first pass the clinical expert review, and then enter the health insurance bureau's negotiation (bidding) stage, the remaining level can pass is still to be seen, clinical experts and the attitude of the health insurance bureau is still unknown.
10. Can the controversial variety catch the health care bus? This year's list of medical insurance preliminary examination there are some local inclusion in the "assisted drug" or "focus monitoring" catalog of products, such as blood must be net injections during the agreement period, in Henan, Anhui, Gansu and other places have entered the auxiliary drug catalog, in addition to anhui, Yunnan, Changzhi, Wuxi, mad shop and other provinces and cities auxiliary drug catalog or key monitoring catalog of injection dansan products in the list.
similar products for the exclusive variety, after the local restrictions, whether it can pass expert review, negotiation bidding, to catch the health care shuttle remains in doubt.
.